DAO DEFICIENCY SCREENING AMONG PATIENTS WITH INSOMNIA SYMPTOMS

AB Biotek

Status: Completed

Conditions: Insomnia Disorder; Insomnia

Study type: Observational

Funder types: Industry

Identifiers

NCT06488027

DAO-SLEEP-2022

Details and patient eligibility

About

Insomnia is prevalent in the global population. Diamino oxidase (DAO) is an enzyme that degrades histamine. When there is not enough DAO enzyme activity in the body, histamine accumulates and it can lead to symptoms in the nervous system, among others. In this study we wanted to study the prevalence of DAO deficiency in pacients with insomnia symptoms.

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Older than 18 years old
• With one or more symptoms of insomnia
• Explicit acceptance to participate to the study through informed consent

Exclusion criteria

• Insomnia symptoms that could be justified by the existance of another sleep pathology (e.g., narcolepsy)

Trial design

200 participants in 1 patient group

Patients with insomnia symptoms

Description:

Patients with insomnia symptoms visiting AdSalutem sleep center